In one paragraphArticle in Research square, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 81 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
10 authors at 4 institutions in 2 countries.
Peter HalfmannInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison.
Seth ZostVanderbilt Vaccine Center, Vanderbilt University Medical Center; Department of Pediatrics Vanderbilt University Medical Center.ORCID 0000-0001-6712-5076 James CroweVanderbilt Vaccine Center, Vanderbilt University Medical Center; Department of Pediatrics Vanderbilt University Medical Center; Department of Pathology, and Microbiology and Immunology, Vanderbilt University Medical Center.ORCID 0000-0002-0049-1079 Lisa PurcellVir Biotechnology.
Yoshihiro KawaokaInfluenza Research Institute, Department of Pathobiological Sciences, School of Veterinary Medicine, University of Wisconsin-Madison; Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo; The Research Center for Global Viral Diseases, National Center for Global Health and Medicine Research Institute, Tokyo.ORCID 0000-0001-5061-8296 Daved FremontDepartment of Pathology & Immunology, Washington University School of Medicine; Department of Molecular Microbiology, Washington University School of Medicine; Department of Biochemistry & Molecular Biophysics, Washington University School of Medicine.ORCID 0000-0002-8544-2689 Michael DiamondDepartment of Medicine and Department of Pathology & Immunology and Department of Molecular Microbiology, Washington University School of Medicine; Andrew M. and Jane M. Bursky Center for Human Immunology and Immunotherapy Programs, Washington University School of Medicine; Center for Vaccines and Immunity to Microbial Pathogens, Washington University School of Medicine.ORCID 0000-0002-8791-3165 University of Wisconsin–Madison · USVanderbilt University Medical Center · USVir Biotechnology (Switzerland) · CHVIR Biotechnology (United States) · US
Funding
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA VACCINE RESEARCH75N93019C00051 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KRAMMER, FLORIAN · 2019 to 2025
$105.4MNIAID Centers of Excellence for Influenza Research and Response: Universal Influenza Vaccine Research Activities75N93021C00014 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI GARCIA-SASTRE, ADOLFO · 2021 to 2025
$62.6MEmerging infections: surveillance, epidemiology and pathogenesisU01AI151810 · NIAID · WASHINGTON UNIVERSITY · PI Adrianus CM Boon, DAVID WANG · 2020 to 2026
$10.0MHuman antibody-based countermeasures against the Wuhan Coronavirus SARS-CoV-2R01AI157155 · NIAID · WASHINGTON UNIVERSITY · PI BARIC, RALPH S, CROWE, JAMES E · 2020 to 2024
$6.0MNIAID NIH HHS 75N93019C00051NIAID NIH HHS 75N93021C00014NIAID NIH HHS HHSN272201700060CNIAID NIH HHS R01 AI157155NIAID NIH HHS U01 AI151810
6 · The paper itselfAbstract
The emergence of the highly-transmissible B.1.1.529 Omicron variant of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is concerning for antibody countermeasure efficacy because of the number of mutations in the spike protein. Here, we tested a panel of anti-receptor binding domain monoclonal antibodies (mAbs) corresponding to those in clinical use by Vir Biotechnology (S309, the parent mAb of VIR-7831 [Sotrovimab]), AstraZeneca (COV2-2196 and COV2-2130, the parent mAbs of AZD8895 and AZD1061), Regeneron (REGN10933 and REGN10987), Lilly (LY-CoV555 and LY-CoV016), and Celltrion (CT-P59) for their ability to neutralize an infectious B.1.1.529 Omicron isolate. Several mAbs (LY-CoV555, LY-CoV016, REGN10933, REGN10987, and CT-P59) completely lost neutralizing activity against B.1.1.529 virus in both Vero-TMPRSS2 and Vero-hACE2-TMPRSS2 cells, whereas others were reduced (COV2-2196 and COV2-2130 combination, ~12-fold decrease) or minimally affected (S309). Our results suggest that several, but not all, of the antibodies in clinical use may lose efficacy against the B.1.1.529 Omicron variant.
Identifiers
PMID34981042
PMCPMC8722605
OpenAlexW4200121261
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390